Researchers found that people with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer who received first-line lorlatinib treatment had significantly improved progression-free survival, as well as significantly higher objective and cranial response rates, compared with those who were given first-line crizotinib. The findings, presented at the virtual congress of the European Society of Medical Oncology, also correlated lorlatinib with better quality of life as reported by patients.
First-line lorlatinib beneficial in ALK-positive NSCLC
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.